ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2206

Joint Repair While Initiating Biologic Therapy in Rheumatoid Arthritis

Scott Brunet1,2,3, Sarah Manske1,2,3, Klaus Engelke4,5, Steven K. Boyd1,2,3 and Cheryl Barnabe2,6, 1Biomedical Engineering, University of Calgary, Calgary, AB, Canada, 2McCaig Institute for Bone and Joint Health, Calgary, AB, Canada, 3Department of Radiology, University of Calgary, Calgary, AB, Canada, 4Institute of Medical Physics, University of Erlangen, University of Erlangen-Nuremberg, Erlangen, Germany, 5Department of Medicine, Erlangen University Hospital, Erlangen, Germany, 6Division of Rheumatology, University of Calgary, Calgary, AB, Canada

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Biologics, Bone, HR-pQCT, Imaging and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Tuesday, October 23, 2018

Session Title: Imaging of Rheumatic Diseases Poster III: Other Modalities

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Functional decline and reduced quality of life for patients with rheumatoid arthritis (RA) results from chronic changes to joints in patients, including bone erosions and joint space narrowing. Advanced biologic therapies can prevent joint damage progression, and it has been suggested that they can repair bone damage 1,2. High resolution peripheral quantitative computed tomography (HR-pQCT) provides measurement of joint space and bone microstructure with high sensitivity and precision. The purpose of this study was to investigate whether HR-pQCT can detect joint damage repair in patients initiating biologic therapies, and whether changes in joint damage are associated with changes in clinical outcomes.

 

Methods: We recruited 88 participants who met the ACR/EULAR 2010 Classification Criteria for RA and were starting on a new biologic agent due to moderate or high disease activity. The 2nd and 3rd MCP joints of the dominant hand were scanned with a HR-pQCT scanner (XtremeCTII, Scanco Medical, 61mm) at 3 and 12 months after initiating the new agent. Participants also underwent a rheumatologist examination for disease activity and self-reported measures of physical (Health Assessment Questionnaire) and hand (DASH Questionnaire) function were collected at these visits, along with the Jebsen hand function test. Joint space volume (JSV) was measured in 3D using an algorithm developed by the SPECTRA collaboration3 (Figure 1) . Bone erosion quantification will be completed using a 3D segmentation technique using MIAF-Finger4. Individual changes in JSV were classified as increased or decreased if the absolute changes were greater than detection limits based on least significant change.

 

Results: The cohort was 72.7% female with an average disease activity score (DAS28) of 2.58 at baseline and 2.60 at 9 month follow-up. The average DASH score was decreased to 27.6 from 29.3, while the average HAQ score increased to 0.89 from 0.86. There were no statistically significant changes in clinical results. When compared to detection limits, 73 of the 84 analyzable joints showed no change in joint space volume, 5 showed an increase and 6 showed a decrease . We found no significant relationships between joint space outcome and disease activity, physical function, or hand function.

 

Conclusion: In most patients there were no significant changes in joint space as they initiate or change biologic therapies. This may be due to a large detection limit making it difficult to detect changes over a 9 month period. Future erosion analysis will provide further insight on the potential benefits of biologic therapy with regards to the reversibility of bone damage as seen on HR-pQCT.

References:

1. Van Der Heijde D. Ann Rheum Dis. 2011. 2. Schett G, et al. Arthritis Res Ther. 2011. 3. Stok KS, et al.Osteoarthr Cartil. 2017.4. Töpfer D, et al. Rheumatol (United Kingdom). 2014.

 

 

Figure 1. 3D visualizations of joints with a large JSV (left) and a small JSV (right).

 


Disclosure: S. Brunet, None; S. Manske, None; K. Engelke, None; S. K. Boyd, None; C. Barnabe, None.

To cite this abstract in AMA style:

Brunet S, Manske S, Engelke K, Boyd SK, Barnabe C. Joint Repair While Initiating Biologic Therapy in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/joint-repair-while-initiating-biologic-therapy-in-rheumatoid-arthritis/. Accessed April 13, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/joint-repair-while-initiating-biologic-therapy-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.